Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
